Over 50 combined years of medical practice and product innovation
Leadership Team
Evan C. Unger, MD, FACR
Interim Chief Executive Officer
Evan Unger M.D. is a renowned expert on ultrasound contrast media. He founded MVT to advance the field of ultrasound contrast agents and theranostics. Dr. Unger has also founded three other biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs, including Definity®, the world’s #1 selling ultrasound contrast agent. ImaRx Pharmaceutical was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using ultrasound and microbubbles to treat ischemic stroke. Dr. Unger co-founded NuvOx, a clinical-stage biotech company that is in Phase II trials for stroke and brain cancer. He is a co-inventor on the issued U.S. patent covering MVT-100 and also an inventor on over 120 other issued US patents. He is a board-certified radiologist and has had an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona and serves as President and CEO of NuvOx Pharma.
Emmanuelle J. Meuillet, PhD
Chief Operating and Scientific Officer
Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She has had an appointment as an Associate Professor at the University of Arizona. Over the years, Dr. Meuillet has managed many NIH funded programs in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, PHusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH and DoD. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on five patents and she belong to several editorial boards for specialized cancer journals. She joined Microvascular Therapeutics in 2018.
Thom Tulip, PhD
Chief Business Officer
Seasoned business executive with 30+ years in the field of imaging. Tulip has decades of experience developing and successfully commercializing imaging agents, which have enabled improved patient management in cardiology, oncology, and neurology. He initiated the licensing of what became Definity from Prof. Unger to DuPont Medical Imaging and led the approval and launch of the ultrasound contrast agent in non-US geographies as VP of International Operation at BMS Medical Imaging, now Lantheus. He has been instrumental in the regulatory approvals of more than fifteen (15) new chemical entities and expanded indications and has successfully launched numerous clinical imaging agents. Most recently, he was CBO at Radiopharm Theranostics, a clinical-stage biopharma company developing breakthrough cancer imaging biomarkers and therapies.
Chief Medical Officer
Marty Rosenberg, MD
Dr. Rosenberg is a graduate of Temple University School of Medicine and trained in general surgery at Albert Einstein Medical Center in Philadelphia. He joined Squibb Diagnostics in 1990 and worked on the clinical development and approval of two novel oral contrast agents from ImarX pharmaceuticals: SonoRx and LumenHance. In 1996, he was hired by Bristol-Myers Squibb Medical Imaging, formerly DuPont Pharma, to develop the ultrasound contrast agent Definity (DMP-115), also invented by Imarx pharmaceuticals. Dr. Rosenberg is currently working for Bayer Radiology where he led the initial approval and additional indications for Gadavist in the US.
David Lim, BS, MBA
Director of Finance
David received a Bachelor of Science degree from Rutgers University, and an MBA from NYU Stern School of Business. David has extensive experience in financial markets both public and private, and asset management industry. He Co-Founded Washington Square Capital, which focuses on making acquisitions of privately held businesses. Previously, he worked as a trader for a subsidiary of Royal Bank of Canada, with $40B in assets under management by the time David left the firm. His experience also includes being a proprietary trader. As a trader, David researched and developed investments to be implemented for the firm’s portfolios and funds, while mitigating risk. In addition to his finance experience, David has advised on transactions for commercial real estate in New York City. He has played a critical role in the due diligence process for several investments. He is currently an Advisor for a Web 3 company Plato.
Board of Directors
Evan C Unger, MD
Chairman of the Board
Timothy Healey, BS, MBA
Mr. Healey’s executive experience includes serving as Chief Commercial Officer - Complete Commercialization at EVERSANA™, Senior Vice President, Commercial at Lantheus Medical Imaging, Vice President/General Manager for US Virology at Abbott Laboratories/AbbVie, Senior Vice President, Commercial at AMAG Pharmaceuticals, and Executive Director of CNS Marketing at Sepracor. During his tenure at Lantheus, Mr. Healey was responsible for worldwide sales and marketing of Definity®, the #1 selling ultrasound contrast agent. At Sepracor, Mr. Healey orchestrated the launch of Lunesta® (Sleep), one of the most successful launches to date, generating more than 4 million prescriptions in the first year of launch. He has also played key roles in the launches of Feraheme ® (Nephrology), as well as new indications for Allegra® (Allergy). He has won prestigious awards for launch excellence including Brandweek’s “Marketer of the Year,” and Medical Marketing a Media’s “Brand Team of the Year.” Mr. Healey received a Bachelor of Science degree from Boston College, and a Masters in Business Administration from Babson College where he was inducted into the Beta Gamma Sigma Scholastic Honorary Society.
Shiv Kapoor, BA, MBA
Shiv Kapoor has over 25 years of experience in business strategy, finance, investments, investor relations, research and regulatory fields in companies such as Johnson & Johnson, Citigroup, Montgomery & Co., Alza Corporation, and Spectrum Pharmaceuticals. He is also the founder of cancer focused biotechnology company, BioRamon Pharmaceuticals. Mr. Kapoor has been a top ranked analyst on both the buy and sell sides of Wall Street. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. Mr. Kapoor holds a BA in Biochemistry UC Berkeley, and an MBA from The University of Chicago Booth School of Business.
Amy Huang, MBA
Amy Huang is a venture capitalist with a background in finance and business strategy. Co-Founder and Managing Partner at ARCHina Capital, Investor in Luminar. She was ranked by Forbes as one of the top 100 female venture capitalists in the world. Ms. Huang has an MBA from Wharton school of business.
Board of Scientific Advisors
John Pacella, MD, MS
Dr. John Pacella is an Interventional Cardiologist within the University of Pittsburgh Medical Center (UPMC) Heart and Vascular Institute. He is an Associate Professor of Medicine and Bioengineering at the University of Pittsburgh and holds an adjunct appointment as an Associate Professor of Biomedical Engineering at Carnegie Mellon University. He earned his bachelor’s degree in mechanical engineering with a biomedical emphasis from Carnegie Mellon University, his master’s degree in mechanical engineering from Lehigh University, and his medical degree from the University of Pittsburgh. Dr. Pacella is an accomplished researcher with interests broadly spanning microcirculation, sonothrombolysis, novel interventional cardiology device design, portable ultrasound, and novel microbubble formulations. He has worked on numerous grants from a variety of funding sources, has published many articles in peer-reviewed journals, and regularly presents at national and international conferences. He holds 6 patents and has received several awards for his research, including the prestigious American Society of Echocardiography Arthur E. Weyman Young Investigator Award.
